Cargando…
Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity
BACKGROUND: The donepezil-memantine combination is a US Food and Drug Administration (FDA)–approved medication to treat Alzheimer’s disease (AD). Galantamine is superior to donepezil because it is a positive allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (α7nAChR). Although gal...
Autores principales: | Koola, Maju Mathew, Nikiforuk, Agnieszka, Pillai, Anilkumar, Parsaik, Ajay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457262/ https://www.ncbi.nlm.nih.gov/pubmed/30984874 |
Ejemplares similares
-
Galantamine-memantine combination effective in dementia: Translate to dementia praecox?
por: Koola, Maju Mathew, et al.
Publicado: (2018) -
Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine
por: Koola, Maju Mathew
Publicado: (2016) -
Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010) -
Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
por: Majláth, Zsófia, et al.
Publicado: (2016) -
Pharmacogenetics of Donepezil and Memantine in Healthy Subjects
por: Ovejero-Benito, María C., et al.
Publicado: (2022)